The 2021 Personalis NeXT Level Biomarkers Symposium showcased the latest research from Personalis’ ImmunoID NeXT Platform™ and highlighted key applications of the most comprehensive immunogenomics solution for translational research. The Personalis Research and Development team presented the latest insights and applications from our internal research and highlighted the technical capabilities of ImmunoID NeXT. A presentation from one of our collaboration partners, the Parker Institute for Cancer Immunotherapy, also demonstrated how the ImmunoID NeXT Platform is impacting real world biomarker discovery in clinical trials.
The 2021 NeXT Level Biomarkers Symposium covered novel research put forth by the Personalis R&D team as well as a client presentation from our partners at the Parker Institute for Cancer Immunotherapy. Topics included:
- HLA LOH and HLA typing using our Deletion of Allele-Specific HLAs (DASH) technology
- Neoantigen prediction capabilities using our Systematic HLA Epitope Ranking Pan Algorithm (SHERPA)
- NeXT Dx and companion diagnostics development from NGS data
- Case study on leveraging the data from Personalis’ ImmunoID NeXT Platform from the Parker Institute for Cancer Immunotherapy